Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985807%3A_____%2F24%3A00585914" target="_blank" >RIV/67985807:_____/24:00585914 - isvavai.cz</a>

Alternative codes found

RIV/00669806:_____/24:10478854

Result on the web

<a href="https://doi.org/10.1016/j.jacadv.2024.100880" target="_blank" >https://doi.org/10.1016/j.jacadv.2024.100880</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jacadv.2024.100880" target="_blank" >10.1016/j.jacadv.2024.100880</a>

Result language

angličtina

Original language name

Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry

Original language description

BACKGROUND: Managing patients with atrial fibrillation (AF) and worsening renal function (WRF) remains a clinical challenge due to the need of dose adjustment of non-vitamin K antagonist oral anticoagulants. Objectives: To determine the incidence of WRF in patients with AF treated with edoxaban, the association of WRF with clinical outcomes, and predictors of WRF and clinical outcomes in these patients. METHODS: This is a subanalysis of the Edoxaban Treatment in routine clinical practice for patients with non-valvular Atrial Fibrillation in Europe study (NCT02944019), an observational study of edoxaban-treated patients with AF. WRF was defined as a ≥25% reduction in creatinine clearance between baseline and 2 years. RESULTS: Of the 9,054 patients included (69% of the total 13,133 enrolled), most did not experience WRF (90.3%) during the first 2 years of follow-up. WRF occurred in 9.7% of patients. Patients with WRF had significantly higher rates of all-cause death (3.88%/y vs 1.88%/y, P < 0.0001), cardiovascular death (2.09%/y vs 0.92%/y, P < 0.0001), and major bleeding (1.51%/y vs 0.98%/y, P = 0.0463) compared with those without WRF. Rates of intracranial hemorrhage (0.18%/y vs 0.18%/y) and of any stroke/systemic embolic events were low (0.90%/y vs 0.69%/y, P = 0.3161) in both subgroups. The strongest predictors of WRF were a high CHA2DS2-VASc score, high baseline creatinine clearance, low body weight, and older age. Most predictors of WRF were also predictors of clinical outcomes. CONCLUSIONS: WRF occurred in approximately 10% of edoxaban-treated AF patients. Rates of death and major bleeding were significantly higher in patients with WRF than without. Stroke events were low in both subgroups.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

JACC Advances

ISSN

2772-963X

e-ISSN

—

Volume of the periodical

3

Issue of the periodical within the volume

4

Country of publishing house

US - UNITED STATES

Number of pages

17

Pages from-to

100880

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-85186969798